Press Releases

 
Press Releases
Date Title and Summary View
Feb 9, 2017 BOSTON, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and Chief Executive Officer of ...
Nov 9, 2016 BOSTON, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, today announced its third quarter 2016 financial results. ...
Sep 20, 2016 BOSTON, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that the Company has recently initiated dosing in the multiple ascending dose (MAD) cohorts of its ongoin...
Aug 4, 2016 BOSTON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its second quarter 2016 financial results. "The compelling...
Aug 3, 2016 BOSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, President and Chief Executive Officer of Zafgen, will present at ...
Jul 19, 2016 -ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical Development Priorities- -Strong Cash Position Sufficient to Fund Operat...
Jun 11, 2016 NEW ORLEANS, June 11, 2016 (GLOBE NEWSWIRE) -- Zafgen Inc. (NASDAQ:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced new data from the ZAF-203 clinical trial evaluating beloranib, a MetAP2 inhibitor...
May 10, 2016 BOSTON, May 10, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its first quarter 2016 financial results, and provided an update on the Company's clinical program for belor...
May 3, 2016 BOSTON, May 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will host a conference call on Tuesday, May 10, 2016 at 4:30 p.m. ET to discuss i...
Apr 3, 2016 --bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improvement in hyperphagia-related behaviors in PWS patients-- --Beloranib was associated with improvement in total cholesterol, LDL cholesterol and other markers of cardiometabolic risk -- ...
Page:
1
... NextLast
= add release to Briefcase